Arcturus Therapeutics Holdings (ARCT) closed at $9.39 on November 10, 2026, down 1.1% from the previous close, on volume of 819,078 shares (30-day average 664,486).
Data as of November 10, 2026.
Canaccord Genuity Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)
TipRanks (Mon, 9-Nov 7:55 AM ET)
Wells Fargo Reaffirms Their Buy Rating on Arcturus Therapeutics (ARCT)
TipRanks (Fri, 6-Nov 9:35 AM ET)
Arcturus Therapeutics (ARCT) Gets a Buy from B. Riley Securities
TipRanks (Fri, 6-Nov 9:35 AM ET)
TipRanks (Fri, 6-Nov 9:05 AM ET)
Arcturus Therapeutics GAAP EPS of -$0.26 beats by $0.44, revenue of $18.3M beats by $10.26M
Seeking Alpha News (Thu, 5-Nov 4:42 PM ET)
Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress
Business Wire (Thu, 5-Nov 4:01 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 5-Nov 10:00 AM ET)
Business Wire (Mon, 26-Oct 4:01 PM ET)
Business Wire (Wed, 23-Sep 4:01 PM ET)
Business Wire (Fri, 18-Sep 9:00 AM ET)
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Arcturus Therapeutics Holdings trades on the NASDAQ stock market under the symbol ARCT.
As of November 10, 2026, ARCT stock price declined to $9.39 with 819,078 million shares trading.
ARCT has a beta of 2.75, meaning it tends to be more sensitive to market movements. ARCT has a correlation of 0.14 to the broad based SPY ETF.
ARCT has a market cap of $270.64 million. This is considered a Small Cap stock.
Last quarter Arcturus Therapeutics Holdings reported $18 million in Revenue and -$.26 earnings per share. This beat revenue expectation by $10 million and exceeded earnings estimates by $.40.
In the last 3 years, ARCT traded as high as $45.00 and as low as $5.50.
The top ETF exchange traded funds that ARCT belongs to (by Net Assets): ARKG, VTI, IWM, VXF, IWN.
ARCT has underperformed the market in the last year with a price return of +7.7% while the SPY ETF gained +12.9%. However, in the short term, ARCT had mixed performance relative to the market. It has outperformed in the last 3 months, returning +26.7% vs -2.8% return in SPY. But in the last 2 weeks, ARCT shares have been beat by the market, returning -5.2% compared to an SPY return of -2.0%.
ARCT support price is $8.86 and resistance is $10.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARCT shares will trade within this expected range on the day.
